US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.

The US company listed in the UK has been devastated by the failure of its investigational eczema drug in Phase II trials in August and has hired an advisor to look for strategic alternatives, including a sale.

Realm Therapeutics is evaluating a substance derived from insights into innate immunity that has potential as an immunomodulator in various dermatological disorders, including atopic dermatitis and acne, with proof-of-concept (POC) expected in the third quarter.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.